Sign Up for Free!

Continue Analyzing the page and more.

Continue with Google

Already have an Account? Log In

The Trial has ended

Continue Analyzing the page and more.

Upgrade to Pro
Home Daily Intelligence Tracker
    • Plans Blog Contact
    Amgen Inc logo
    AMGN

    Amgen Inc

    MaveScore 53 Low model confidence
    Last Price US$364.69 As of Jul 10, 2026
    DCF Fair Price US$210.29 Research estimate · Jul 10, 2026 -42.3% vs price
    Market Cap US$201.9b Company size context
    7D Performance -2.69% Past 7 days
    1Y Performance 21.18% Past 12 months
    Model Rating
    Historical model output for research review

    Fundamental data date

    Mar 31, 2026

    102 days old

    Market price date

    Jul 10, 2026

    1 day old

    Coverage

    16/16

    No missing model inputs

    Data quality

    Excellent

    Current stored snapshot

    Transparent research score

    Why the model scores this stock

    MaveScore is a research prioritization score from 0 to 100. It is historical model output for watchlist review, not personalized financial advice.

    MaveScore 53 Low confidence

    Stored data quality

    Freshness and coverage checks

    16/16 Current stored snapshot

    Quality

    20/35 Mixed

    Blends latest model rank with profitability and dilution ranks.

    Financial Strength

    17/25 Mixed

    Rewards durable profitability, margins, and positive free cash flow.

    Valuation Support

    2/15 Weak

    Favors positive earnings, positive cash flow, and lower multiples.

    Momentum

    6/15 Weak

    Highlights research candidates with supportive 3-month and 6-month price regimes.

    Shareholder Alignment

    8/10 Strong

    Rewards less dilutive share behavior and enough size for liquid research coverage.

    Positive model output

    • Rewards less dilutive share behavior and enough size for liquid research coverage.

    Research risks to review

    • Favors positive earnings, positive cash flow, and lower multiples.
    • Highlights research candidates with supportive 3-month and 6-month price regimes.

    MaveScore uses historical model inputs, stored company fundamentals, and stored price context for research support only. Review missing inputs and business-specific risks before acting.

    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Amgen Inc Overview

    Industry: Drug Manufacturers General

    Sector: Healthcare

    Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California. Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, an Read More

    Amgen Inc is evaluated based on the investment philosophy and approach to stock market investing developed by renowned investor Warren Buffett. Companies with high ratings typically exhibit growing earnings, a substantial profit margin, conservative leverage, a consistently high return on equity, and a sustained practice of repurchasing their shares over the years.

    Amgen Inc

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed Apr 30, 2026

    Quarterly result summary

    Revenue was $37.1B (reported); EPS was $4.9 (reported).

    Revenue $37.1B reported
    EPS $4.9 reported
    Operating income $2.7B +126% YoY
    Net income $1.8B +5% YoY

    What changed

    • Revenue reported to $37.1B; EPS reported to $4.9.
    • Operating income +126% YoY to $2.7B.
    • Net income +5% YoY to $1.8B.

    Guidance / outlook

    the Company expects: • Total revenues in the range of $37.1 billion to $38.5 billion.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 10-Q May 01, 2026 SEC filing 8-K Apr 30, 2026 SEC filing 10-K Feb 13, 2026 SEC filing 8-K Feb 03, 2026 Earnings release EARNINGS RELEASE Feb 03, 2026 SEC filing 10-Q Nov 05, 2025 SEC filing 8-K Nov 04, 2025 Earnings release EARNINGS RELEASE Nov 04, 2025 SEC filing 10-Q Aug 06, 2025 Earnings release EARNINGS RELEASE Aug 05, 2025 SEC filing 8-K Aug 05, 2025

    Recent News



    Panagora Asset Management Inc. Has $136.94 Million Holdings in Amgen Inc. $AMGN
    1 hour ago
    Amgen Inc. $AMGN is Round Hill Asset Management's 2nd Largest Position
    1 hour ago
    Amgen Inc. $AMGN Shares Sold by Mackenzie Financial Corp
    6 minutes ago

    Earnings Per Share

    Score 2.00/5
    Amgen Inc earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Drug Manufacturers General industry , Merck & Company Inc , Eli Lilly and Company , Johnson & Johnson are companies with high ratings.

    Return on Equity

    Score 3.80/5
    Amgen Inc stands out with a superior score in the Return on Equity (ROE) section, surpassing the sector median value and showcasing its strong performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Amgen Inc AMGN US$201.9b
    Zoetis Inc ZTS US$31.4b
    IQVIA Holdin... IQV US$34.6b
    Agilent Tech... A US$36.9b

    Net Margin

    Score 3.91/5
    Amgen Inc commands a high score, propelled by its net margin consistently outpacing the sector median value and exhibiting continuous growth in recent six years; noteworthy counterparts in the sector, boasting similarly high scores, include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Amgen Inc AMGN US$201.9b
    Zoetis Inc ZTS US$31.4b
    IQVIA Holdin... IQV US$34.6b
    Agilent Tech... A US$36.9b

    Share Buyback

    In Drug Manufacturers General industry , Merck & Company Inc , Eli Lilly and Company , Johnson & Johnson are companies with high ratings.

    Leverage

    Score 1.14/5
    Amgen Inc registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc have achieved high scores.
    Amgen Inc AMGN US$201.9b
    Zoetis Inc ZTS US$31.4b
    IQVIA Holdin... IQV US$34.6b
    Agilent Tech... A US$36.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    SEC financial statements are temporarily unavailable.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Amgen Inc logo

    Amgen Inc

    US$364.69

    US$210.29

    -42.3% vs price

    US$201.9b

    -2.69%

    21.18%